Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7493311 | 0.85 | KMT2A (0.50) | KMT2ANPSR1L3MBTL1PDE4DPOLB | |
| SCHEMBL5355569 | 0.81 | MAPK1 (0.62) | HCAR2KMT2AL3MBTL1POLBCYP1A2 | |
| SCHEMBL1665229 | 0.81 | DAO (0.58) | HCAR2KMT2ANPSR1L3MBTL1PDE4D | |
| SCHEMBL1423671 | 0.79 | KMT2A (0.54) | HCAR2KMT2ANPSR1L3MBTL1PDE4D | |
| SCHEMBL163302 | 0.79 | KMT2A (0.54) | KMT2ANPSR1L3MBTL1PDE4DPOLB | |
| SCHEMBL1007015 | 0.79 | MAPK1 (0.61) | KMT2ANPSR1L3MBTL1PDE4DPOLB | |
| SCHEMBL13369577 | 0.79 | NPSR1 (0.52) | KMT2ANPSR1L3MBTL1PDE4DPOLB | |
| SCHEMBL25973886 | 0.78 | L3MBTL1 (0.49) | KMT2ANPSR1L3MBTL1PDE4DPOLB | |
| SCHEMBL930612 | 0.78 | KMT2A (0.52) | KMT2ANPSR1L3MBTL1PDE4DPOLB | |
| Ethane SCHEMBL6614658 | 0.78 | MAPK1 (0.59) | KMT2ANPSR1L3MBTL1PDE4DPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4522155-A1 | NOVEL EXTENSION-FUNCTIONALIZATION STRATEGY FOR WATER-HARVESTING MOFS | The Regents of the University of California (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2025051242-A1 | RAS INHIBITOR | 泰励生物科技（上海）有限公司 | 2025-03-13 | — | — | WO | disclosed |
| CN-119591588-A | RAS inhibitors | 泰励生物科技（上海）有限公司 | 2025-03-11 | — | — | CN | disclosed |
| US-20250066392-A1 | Extension-Functionalization Strategy for Water-Harvesting MOFs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-02-27 | — | — | US | disclosed |
| CN-119212697-A | Novel extension functionalization strategy for water-collecting MOF | 加利福尼亚大学董事会 | 2024-12-27 | — | — | CN | disclosed |
| WO-2023220514-A1 | NOVEL EXTENSION-FUNCTIONALIZATION STRATEGY FOR WATER-HARVESTING MOFS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2020054670-A1 | NOVEL HETEROAROMATIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME | 科研製薬株式会社 | 2020-03-19 | — | — | WO | disclosed |
| US-20070032537-A1 | 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases | ARENA PHARMACEUTICALS, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032537-A1 | 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases | ARENA PHARMACEUTICALS, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032537-A1 | 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases | ARENA PHARMACEUTICALS, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| EP-1633351-A1 | 5-SUBSTITUTED 2H-PYRAZOLE-3-CARBOXYLIC ACID DERIVATIVES AS AGONISTS FOR THE NICOTINIC ACID RECEPTOR RUP25 FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | Arena Pharmaceuticals, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2005011677-A1 | 5-SUBSTITUTED 2H-PYRAZOLE-3-CARBOXYLIC ACID DERIVATIVES AS AGONISTS FOR THE NICOTINIC ACID RECEPTOR RUP25 FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| EP-0904271-A4 | 5,6,7,8-TETRAHYDROPYRIDO[2,3-d]PYRIMIDINES | UNIV PRINCETON (US) | 2002-01-23 | — | — | EP | disclosed |
| US-6066639-A | ANTITUMOR AGENTS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2000-05-23 | — | — | US | disclosed |
| EP-0904271-A1 | 5,6,7,8-TETRAHYDROPYRIDO[2,3-d]PYRIMIDINES | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1999-03-31 | — | — | EP | disclosed |
| WO-1997041115-A1 | 5,6,7,8-TETRAHYDROPYRIDO[2,3-d]PYRIMIDINES | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1997-11-06 | — | — | WO | disclosed |
| US-5470862-A | Intravenous anesthetics | OHMEDA PHARMACEUTICAL PRODUCTS DIVISION INC. (US) | 1995-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066392-A1 | Extension-Functionalization Strategy for Water-Harvesting MOFs | EPCAM, CD44, AQP1 | HCAR2 3384/4885KMT2A 1236/4885NPSR1 2015/4885 |
| US-20070032537-A1 | 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases | ACE, AGTR2, ACE2 | HCAR2 52/4885KMT2A 3934/4885NPSR1 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.